Eli Lilly stock drops 1.12 percent as FDA grants breakthrough therapy

Traders Union
All News
Business & Wealth
Companies
Eli Lilly drops 1.12% today

Highlights

LLY currently trades below near-term moving averages, signaling downward pressure despite maintaining a long-term bullish structure.
Momentum indicators flash mixed signals with oversold readings and recent price weakness, revealing increased downside risk in the short term.
The likely trading range for the coming week is $1,120 to $1,160, with consolidation favored and breakout risk skewed to the upside.

Eli Lilly says this designation will help advance development of the potential therapy. Further information is available online, the company says.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Short-term downward bias as price holds above long-term support

LLY is trading at $1,135.77, currently below both the SMA-20 ($1,184.60) and SMA-50 ($1,147.07), but well above the SMA-200 ($1,024.70). This setup signals short- and medium-term downward pressure with intact long-term bullish structure; the Ichimoku Kijun on D1 sits at $1,181.72, acting as immediate resistance. Near-term support is seen at the EMA-50 ($1,137.95), with key support at the SMA-200 ($1,024.70). Immediate resistance is the Kijun ($1,181.72), followed by key resistance at the SMA-20 ($1,184.60).

Mixed momentum as oversold signals drive extended weekly losses

Momentum indicators present a mixed outlook: MACD on D1 signals strong buy, but ADX is neutral at 19.33. RSI has slipped to 45.69, with CCI and Stoch RSI both oversold, indicating negative momentum and increased downside risk. BBP is oversold at –29.22, showing sellers currently dominate. LLY has fallen $12.89 (1.12%) over the past week from a previous weekly close of $1,148.66, with price testing the very bottom of its weekly range ($1,120.66–$1,232.00) and volatility at 9.94%. The tone remains bearish following a steady decline from the highs. In today's session, the stock is down 1.12%, extending the recent weakness.

Bullish outlook likely as consolidation frames limited downside risk

For the coming week, the expected price range is $1,120 to $1,160, aligning with recent volatility and keeping prices within 3% of the current level. On the W1 timeframe, all major trend indicators (MA-50, RSI, ADX, MACD) signal a bullish structure, meaning the probability of a price increase is high (more than 80%), while the risk of further decline is very low (less than 20%). The baseline scenario calls for sideways consolidation between $1,120 and $1,160. In the bullish case, a breakout above $1,160 may pave the way for a move toward the $1,180–$1,185 resistance cluster. In the bearish scenario, a break below $1,120 opens downside toward the $1,050 area, though this is less likely given strong long-term trend support. The current forecast range keeps LLY near the top half of its 52-week span ($624.40 – $1,249.45).

Previously it was reported that Eli Lilly maintained a bullish technical outlook, driven by strong momentum and positive clinical developments. This article confirms the continued strength in the prevailing scenario, with investors advised to monitor if key support levels remain intact to gauge potential upside or the emergence of near-term risks.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.